Trial Summary
What is the purpose of this trial?This trial is testing a new treatment called NG-641 to see if it is safe for patients with advanced or spreading epithelial tumors. The treatment is given through an IV, and researchers are trying to find the best dose.
Eligibility Criteria
This trial is for adults with advanced epithelial cancers that have failed standard treatments or have no standard options left. Participants must be expected to live at least 6 months, have tumors that can be biopsied safely, and function well in daily life (ECOG status 0-1). They should not have had certain vaccines, major surgeries, or specific treatments recently and must not have active infections or severe autoimmune diseases.Participant Groups
The trial is testing NG-641, a new type of therapy designed to target cancer cells selectively. It's the first time this treatment is being used in humans. The main goal is to see how safe it is and how well patients tolerate it when given to those with metastatic or advanced epithelial tumors.
1Treatment groups
Experimental Treatment
Group I: IntravenousExperimental Treatment1 Intervention
Phase 1a dose escalation: one cycle of treatment.
Phase 1a dose optimisation: up to 8 cycles of treatment
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
UCLASanta Barbara, CA
University of Southern California (USC) - Norris Comprehensive Cancer CenterLos Angeles, CA
Washington University Medical SchoolSaint Louis, MO
MD AndersonHouston, TX
More Trial Locations
Loading ...
Who is running the clinical trial?
PsiOxus Therapeutics LtdLead Sponsor
Akamis BioLead Sponsor